跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
H-1PV
首页
药物
H-1PV
H-1PV
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
H-1 PV EXPRESSING RNAI EFFECTORS
EP 4323533 A1
申请人: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS
优先权: 2021
EP
US
WO
5 件公开
Parvovirus formulation for treating tumors
US 10624935 B2
申请人: DEUTSCHES KREBSFORSCH
优先权: 2015
US
WO
5 件公开
Use of parvovirus for eliminating cancer stem cells (CSCs)
US 9700588 B2
申请人: ROMMELAERE JEAN
优先权: 2010
EP
US
4 件公开
MODIFIED ONCOLYTIC PARVOVIRUS H-1PV WITH AN ENHANCED FITNESS AND SUPERIOR ANTICANCER ACTIVITY
EP 4335448 A1
申请人: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS
优先权: 2022
CN
EP
US
3 件公开
Modified parvovirus having enhanced anti-tumor efficacy
US 8916176 B2
申请人: DEUTSCHES KREBSFORSCH
优先权: 2010
EP
US
3 件公开
Oncolytic virotherapy for therapy of bone cancer
EP 2535055 A1
申请人: DEUTSCHES KREBSFORSCH
优先权: 2011
EP
US
3 件公开
SCALABLE PROCESS FOR ONCOLYTIC RAT PARVOVIRUS H-1 PRODUCTION AND PURIFICATION BASED ON ISOELECTRIC POINT-BASED ELIMINATION OF EMPTY PARTICLES
EP 3321357 A1
申请人: DEUTSCHES KREBSFORSCH
优先权: 2016
EP
US
2 件公开
H-1 PV EXPRESSING RNAI EFFECTORS TARGETING CDK9
EP 3327124 A1
申请人: DEUTSCHES KREBSFORSCH
优先权: 2016
CN
EP
2 件公开
Method for predicting the clinical response of oncolytic parvovirus H1 (H-1PV) treatment in a patient suspected of suffering from cancer by measuring the expression levels of laminins and/or galectins as biomarkers in a patient's sample
US 12516381 B2
申请人: DEUTSCHES KREBS FORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS
优先权: 2018
EP
US
2 件公开
Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of its capsid
US 9234183 B2
申请人: DEUTSCHES KREBSFORSCH
优先权: 2013
US
2 件公开
第 1 / 2 页
上一页
下一页
药物
反馈